New Data Look Positive For Otsuka/Lundbeck’s Brexpiprazole
This article was originally published in PharmAsia News
Executive Summary
Otsuka and Lundbeck have released new Phase III clinical data for their strategically important pipeline drug brexpiprazole, showing positive results in both schizophrenia and major depression from trial programs being used to support a U.S. approval.